Nevimune

Nevimune belongs to a group of HIV drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs) Nevimune is a prescription medicine recognized by the U.S FDA for the prevention of HIV infection in adults and children. Nevimune is always used in combination with other HIV medicines. Nevimune comes in three different forms: immediate-release tablets and oral suspension (a liquid), and extended-release tablets

Nevirapine

Nevimune

200mg

Cipla




Nevimune indication

Nevimune is indicated in co administration with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.

Mechanism of Nevimune

Nevimune isa type of non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Nevimune interpolated directly to reverse transcriptase (RT) and prevents the RNA- dependent and DNA-dependent DNA polymerase action by making a division of the enzyme's catalytic site.

The activities of Nevimune have not refined with template or nucleoside triphosphates.

HIV-2 RT and eukaryotic DNA polymerases such as human DNA polymerases α, ß, γ, or δ are not prohibit by nevirapine.



Pharmacokinetic

Bioavailability in human is 93±9% and 91 ± 8% for oral solution and in rate is 89.7%. High plasma concentration is 2 ± 0.4 mcg/ml attained by 4 hours.

human Albumin of Plasma protein binding is 60%

Nevimune extensively bio transformed via cytochrome P450 and metabolized to several hydroxylated metabolites

Total radioactive in urine is 80% was made up of gluvuronide conjugation. The drug eliminated via urine 81.8 ± 11.1% and feces in 10.1 ± 1.5% Half life is 45 hours




Blueberrypharma.com-img1

Nevimune
Brand Nevimune
Ingredients Nevirapine
Strength 200mg
Manufactured Cipla
Rating

For adult recommended dose

In Co administration with other antiretroviral agents the recommended dose for Nevimune is one tablet of 200 mg daily for the first 14 days, followed by one 200 mg tablet twice daily, The 14-day lead-in period with Nevimune 200 mg daily dosing should be strictly followed as the lead-in period has been observed to decrease the incidence of rash.

If rash continueapart from the 14-day lead-in period, do not dose expand to 200 mg twice daily. The 200 mg once-daily dosing drugs should not be continued above 28 days, at which point, an alternative drugs should be desired. For combination administered antiretroviral therapy, Thenormal dosage and monitoring should be followed.

For pediatrics

The recommended oral dose for pediatric patients 15 days and older :150 mg/m 2 given once daily for period of 14 days followed by 150 mg/m 2 administered twice daily thereafter. The entiredose for daily should not exceed 400 mg for any patient.

Common side effects may include

Skin rash; or changes in the s location of body fat (specifically in your arms, legs, face, neck, breasts, and waist).

Serious side effects

Fever, night sweats, Swollen glands, Mouth sores, diarrhea, stomach pain, weight loss; Chest pain (specifically when you breathe), Dry cough, wheezing, feeling short of breath; cold sores, sores on your genital or anal area; Rapid heart rate, Feeling anxious or irritable, Weakness or prickly feeling, Problems with balance or eye movement; Trouble speaking or swallowing, Severe lower back pain, Loss of bladder or bowel control; or Swelling in your neck or throat (enlarged thyroid), Menstrual changes, Impotence, Loss of interest in sex.

Contraindication

Patients are contraindicated with moderate or severe (Child-Pugh Class B or C, respectively) hepatic impairment For indicated as part of occupational and non-occupational post-exposure prophylaxis (PEP) drugs.

Skin reaction

Serious and life-threatening skin reactions, involves fatal cases, have been reported in patients taking Nevimune .

Hepatotoxicity and hepatic impairment

Serious life-threatening in patient, and in some cases fatal hepatotoxicity, containing fulminant and cholestatic hepatitis, hepatic necrosis and hepatic failure, have been reported in patients treated with Nevimune .

Fat redistribution

Redistribution/aggregation of body fat involves central obesity, buffalo hump (dorsocervical fat enlargement), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy

Drug interactions

Consolidation of Nevimunewith efavirenz is not recommended as this combination has been associated with an increase in adverse reactions and no improvement in efficacy.

Resistance

Immune re-constituents

Immune reconstitution syndrome has been resulted in patients reacted with combination antiretroviral therapy, including Nevimune . During the initial phase of combination antiretroviral treatment, patients whose immune system behave may grow an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, tuberculosis, cytomegalovirus or Pneumocystis jiroveci pneumonia), which may necessitate further evaluation and treatment.



In animal reproduction has no evidence of adverse problem but there is a severe risk in pregnant women solved to nevirapine.There is a pregnancy disclosure registry that monitors pregnancy outcomes in women exposed to Nevimune during pregnancy.

There is no information on the Nevimune effects of on milk production. Due to the possible for HIV-1 transmission (in HIV-negative infants), Introduction viral resistance (in HIV-positive infants), and severe adverse reactions in nursing infants, mothers should not breastfeed if they are gettingNevimune.

Store the drug between 68°F to 77°F (20°C to 25°C). Avoid using ofNevimuneif the original seal over the container opening is broken or missing. Throw away Nevimunethat is no longer needed or expired (out of date). how to safely dispose of unused medicine should Follow FDA guidelines. Keep Nevimuneand all medicines out of reach of children.

If patient missed a dose, patient should be consult with physician and follow the instructions. Follow the regular dosing schedule. Missed dose of drug should be avoided.

Blueberrypharma.com-img2



Quick Contact




Prescription upload






PRESCRIPTION


Blueberrypharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Blueberrypharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Blueberrypharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Blueberrypharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Blueberrypharma.com

At Blueberrypharma.com , a Caregiver can order prescription medicines on your behalf.